UCSF studies illuminate possible new landscape for targeting cancer

Dual UCSF findings dramatize what scientists have just begun to recognize: While so-called oncogenic cells drive the development of cancerous tumors, other, seemingly innocent cells -- inflammatory cells - within emerging tumors can influence the fate of tumors, their aggression and their response to therapy.

The findings, both reported in recent publications, suggest that blocking the action of these 'innocent' cells - or the factors they release - may interrupt the progression of cancerous tumors at early stages of development, the researchers say.

"Tumor biology has historically focused on the cells that contain oncogenic or tumor-suppressor gene mutations. But the combined implication of our two studies suggests that we need to look beyond the mutated tumor cells and into their micro-environment, to take into account the regulation of inflammatory cells," says the lead author of one study, published in Cell, Lisa Coussens, PhD, assistant professor of pathology and a member of the UCSF Comprehensive Cancer Center.

In the Cell study, the researchers report that an enzyme known as matrix metalloproteinase-9 (MMP-9) significantly influences the progression of cancer development in mice engineered to express oncogenes, or tumor-causing genes, that predispose animals to develop squamous cell carcinomas, a common skin cancer in humans. Moreover, the researchers demonstrate that the primary source of the enzyme is not the oncogenic epithelial cells that drive the cancer, but immune inflammatory cells within the tumor's developing mass.

In the other study, published in Nature Cell Biology, the researchers demonstrate that the same enzyme is a key component of the "switch" that initiates angiogenesis, the growth of blood vessels, in mice genetically engineered to develop carcinomas of the pancreatic islets. Angiogenesis supplies emerging tumors with the nutrients and oxygen that are essential for fueling their progressi

Contact: Jennifer O'Brien
University of California - San Francisco

Page: 1 2 3 4 5

Related biology news :

1. Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies
2. UCSD undergraduates participate in collaborative studies abroad on cyberinfrastructure
3. Scientist honored for studies of genetic influence on chemotherapy, tumor development
4. $5 million grant funds partnership, studies of minority-based issues in reproductive health
5. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies
6. $5.5 million awarded to tree-ring research and climate studies
7. Pancreatic cancer blood test & gene studies show promise
8. Two studies weigh in on low-carb diets
9. Animal studies show promise treating severe chronic pain
10. New studies show Curves Program raises metabolic rate in overweight and sedentary women
11. Florida Tech researchers win $912,700 grant for cell studies

Post Your Comments:

(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... In the present market scenario, security is ... industry verticals such as banking, healthcare, defense, electronic gadgets, ... for secure & simplified access control and growing rate ... of bank accounts, misuse of users, , and so ... laptops, and smartphones are expected to provide potential opportunities ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... Chief Financial Officer, will participate in the Piper Jaffray 27 th ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. EST ...
Breaking Biology Technology:
Cached News: